SG10202010156XA - Compositions and methods for making antibodies based on use of an expression-enhancing locus - Google Patents

Compositions and methods for making antibodies based on use of an expression-enhancing locus

Info

Publication number
SG10202010156XA
SG10202010156XA SG10202010156XA SG10202010156XA SG10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA SG 10202010156X A SG10202010156X A SG 10202010156XA
Authority
SG
Singapore
Prior art keywords
expression
compositions
methods
antibodies based
making antibodies
Prior art date
Application number
SG10202010156XA
Inventor
Robert Babb
Darya Burakov
Gang Chen
James Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10202010156XA publication Critical patent/SG10202010156XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
SG10202010156XA 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus SG10202010156XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662325385P 2016-04-20 2016-04-20

Publications (1)

Publication Number Publication Date
SG10202010156XA true SG10202010156XA (en) 2020-11-27

Family

ID=58701850

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202010156XA SG10202010156XA (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus
SG11201807881VA SG11201807881VA (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201807881VA SG11201807881VA (en) 2016-04-20 2017-04-20 Compositions and methods for making antibodies based on use of an expression-enhancing locus

Country Status (15)

Country Link
US (2) US11530277B2 (en)
EP (1) EP3445780A1 (en)
JP (2) JP7134868B2 (en)
KR (2) KR102474757B1 (en)
CN (2) CN116004544A (en)
AR (1) AR108295A1 (en)
AU (1) AU2017253240A1 (en)
BR (1) BR112018071285A2 (en)
CA (1) CA3015371A1 (en)
EA (1) EA201892137A1 (en)
IL (2) IL262268B1 (en)
MX (1) MX2018012866A (en)
SG (2) SG10202010156XA (en)
TW (1) TW201803981A (en)
WO (1) WO2017184831A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210002669A1 (en) * 2017-12-22 2021-01-07 Genentech, Inc. Targeted integration of nucleic acids
WO2020034097A1 (en) * 2018-08-14 2020-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Transcriptional regulatory element and its use in enhancing the expression of exogenous protein
KR102559149B1 (en) * 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 Multispecific antibody screening method using recombinase-mediated cassette exchange
CA3123448A1 (en) * 2018-12-21 2020-06-25 Genentech, Inc. Targeted integration of nucleic acids
JP7250950B2 (en) * 2019-03-29 2023-04-03 エフ． ホフマン－ラ ロシュ アーゲー Methods for generating FcRn-expressing cells by targeted integration of multiple expression cassettes of defined configuration
US20220170047A1 (en) 2019-04-02 2022-06-02 Chugai Seiyaku Kabushiki Kaisha Method of introducing target-specific foreign gene
MX2021015536A (en) 2019-06-19 2022-02-10 Hoffmann La Roche Method for the generation of a protein expressing cell by targeted integration using cre mrna.
JP2022537338A (en) * 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー Methods for generating bivalent bispecific antibody-expressing cells by targeted integration of multiple expression cassettes of defined configuration
MX2021015540A (en) * 2019-06-19 2022-02-10 Hoffmann La Roche Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization.
MX2021015537A (en) 2019-06-19 2022-02-10 Hoffmann La Roche Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization.
EP3986924A1 (en) * 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
TW202342755A (en) * 2021-12-22 2023-11-01 美商建南德克公司 Multi-vector recombinase mediated cassette exchange

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
JP4817657B2 (en) 2002-05-29 2011-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Inducible eukaryotic expression system
AU2003298674A1 (en) 2002-11-14 2004-06-15 Genentech Inc Intron fusion construct and method of using for selecting high-expressing production cell lines
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
MX2008014804A (en) 2006-06-02 2009-01-27 Regeneron Pharma High affinity antibodies to human il-6 receptor.
JP2010514416A (en) 2006-12-21 2010-05-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New method
US20080216185A1 (en) 2007-01-19 2008-09-04 Invitrogen Corporation Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
PT2235064E (en) 2008-01-07 2016-03-01 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2764370C (en) 2009-06-02 2018-08-21 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
AU2010265933B2 (en) 2009-06-26 2015-05-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
RU2015153109A (en) 2009-09-16 2019-01-15 Дженентек, Инк. SUPERSPIRAL AND / OR BINDING PROTEIN COMPLEXES AND THEIR APPLICATIONS
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
MX338953B (en) 2010-08-16 2016-05-06 Novimmune Sa Methods for the generation of multispecific and multivalent antibodies.
MY172718A (en) 2011-08-05 2019-12-11 Regeneron Pharma Humanized universal light chain mice
TW201823460A (en) 2012-05-29 2018-07-01 美商再生元醫藥公司 Production cell line enhancers
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
TWI675044B (en) 2012-11-14 2019-10-21 美商再生元醫藥公司 Recombinant cell surface capture proteins
TWI682941B (en) * 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use
TWI701042B (en) 2014-03-19 2020-08-11 美商再生元醫藥公司 Methods and antibody compositions for tumor treatment
CA2965495C (en) 2014-10-23 2022-05-24 Regeneron Pharmaceuticals, Inc. Cho integration sites and uses thereof
IL258036B (en) 2015-09-23 2022-09-01 Regeneron Pharma Optimized anti-cd3 bispecific antibodies and uses thereof

Also Published As

Publication number Publication date
EA201892137A1 (en) 2019-03-29
CN109071633A (en) 2018-12-21
BR112018071285A2 (en) 2019-02-12
CA3015371A1 (en) 2017-10-26
CN109071633B (en) 2022-11-18
US11530277B2 (en) 2022-12-20
KR20210135340A (en) 2021-11-12
JP2019514358A (en) 2019-06-06
TW201803981A (en) 2018-02-01
US20190263937A1 (en) 2019-08-29
JP7134868B2 (en) 2022-09-12
AR108295A1 (en) 2018-08-08
AU2017253240A1 (en) 2018-09-20
KR102474757B1 (en) 2022-12-07
JP2022164824A (en) 2022-10-27
CN116004544A (en) 2023-04-25
WO2017184831A1 (en) 2017-10-26
MX2018012866A (en) 2019-03-11
EP3445780A1 (en) 2019-02-27
KR20180134894A (en) 2018-12-19
US20230322956A1 (en) 2023-10-12
IL262268B1 (en) 2024-01-01
IL309065A (en) 2024-02-01
SG11201807881VA (en) 2018-10-30
IL262268A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
IL262268A (en) Compositions and methods for making antibodies based on use of an expression-enhancing locus
IL291711A (en) Anti-ctla-4 antibodies and methods of use thereof
IL265800A (en) Anti-lag-3 antibodies and methods of use thereof
IL266918A (en) Anti-ctla-4 antibodies and methods of use thereof
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
IL272274A (en) B7-h4 antibodies and methods of use thereof
IL262266A (en) Compositions and methods for making antibodies based on use of expression-enhancing loci
EP3383430A4 (en) Antibodies and methods of use thereof
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
EP3280441A4 (en) Anti-sortilin antibodies and methods of use thereof
EP3105335A4 (en) Chimeric antigen receptors and methods of making
EP3316909A4 (en) Anti-ntb-a antibodies and related compositions and methods
EP3383917A4 (en) Novel anti-claudin antibodies and methods of use
IL265438A (en) Chimeric antigen receptors and compositions and methods of use thereof
EP3559042A4 (en) Anti-lilrb3 antibodies and methods of use thereof
EP3218370A4 (en) Methods and compositions for inhibition of bromodomain and extraterminal proteins
IL265957A (en) Anti-c1s antibodies and methods of use thereof
EP3443076A4 (en) Compositions and methods of chimeric alloantigen receptor t cells
EP3313993A4 (en) Anti-apobec3 antibodies and methods of making and using
EP3538153A4 (en) Anti-cd46 antibodies and methods of use
EP3365367A4 (en) Anti-bed bug monoclonal antibodies and methods of making and uses thereof
EP3319930A4 (en) Methods and compositions for the stabilizaton of proteins
EP3454864A4 (en) Novel anti-bmpr1b antibodies and methods of use
AU2015901092A0 (en) PAT-SM3 related antibodies and methods of making and using same
AU2014901301A0 (en) PAT-SM3 related antibodies and methods of making and using same